Press Releases

- Expanded the total number of research and development programs from 37 to 48 - Announced first internally-developed NCE is advancing to IND-enabling studies - Planning to expand operations to Canada, with Toronto serving as a multidisciplinary hub - Formed Therapeutics Advisory Board chaired by

Therapeutics Advisory Board to help guide Recursion's growing clinical pipeline through development SALT LAKE CITY, July 13, 2021 / PRNewswire / --  Recursion  (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry,

Recursion and Bright Horizons partner to open child care center in Gateway Mall, next to Recursion's Salt Lake City headquarters SALT LAKE CITY , July 12, 2021 / PRNewswire / -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological

SALT LAKE CITY, July 1, 2021 / PRNewswire / -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning and engineering, today announced that it is doubling the size of its

Recursion to open office space within Mila and build machine learning team to focus on some of drug discovery's most challenging problems MONTRÉAL, June 23, 2021 / PRNewswire / -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological

The company aims to hire up to 50 people by the end of 2021 across disciplines of data science, machine learning, engineering, product management and computational biology. TORONTO, June 15, 2021 / PRNewswire / -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by

Lux Capital, Mubadala Capital, Obvious Ventures, and DCVC among founding group supporting underrepresented founders building next-generation healthcare companies SALT LAKE CITY, June 8, 2021 / PRNewswire / -- Altitude Lab today announced the launch of its Investor Coalition, a partnered network of

SALT LAKE CITY, May 25, 2021 / PRNewswire / -- Recursion Pharmaceuticals, Inc. (Nasdaq : RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning (ML), and engineering, today announced the company

- Strengthened balance sheet with the completion of a successful IPO - Purchased, built, and activated BioHive-1, reportedly the 58th most powerful supercomputer in the world, to accelerate our drug discovery process - Continued development of internal pipeline and partnership programs remain on

SALT LAKE CITY, April 21, 2021 / PRNewswire / -- Recursion Pharmaceuticals, Inc. ("Recursion" or "we")  announced the closing on April 20, 2021 of its initial public offering of 27,878,787 shares of its Class A common stock, which includes the exercise in full of the underwriters' option to